Show simple item record

dc.contributor.authorCook, Mary
dc.contributor.authorChauhan, Aman
dc.date.accessioned2020-10-23T14:18:27Z
dc.date.available2020-10-23T14:18:27Z
dc.date.issued2020-10-12
dc.identifier.urihttp://hdl.handle.net/10713/13913
dc.description.abstractLeveraging the immune system to thwart cancer is not a novel strategy and has been explored via cancer vaccines and use of immunomodulators like interferons. However, it was not until the introduction of immune checkpoint inhibitors that we realized the true potential of immunotherapy in combating cancer. Oncolytic viruses are one such immunotherapeutic tool that is currently being explored in cancer therapeutics. We present the most comprehensive systematic review of all oncolytic viruses in Phase 1, 2, and 3 clinical trials published to date. We performed a systematic review of all published clinical trials indexed in PubMed that utilized oncolytic viruses. Trials were reviewed for type of oncolytic virus used, method of administration, study design, disease type, primary outcome, and relevant adverse effects. A total of 120 trials were found; 86 trials were available for our review. Included were 60 phase I trials, five phase I/II combination trials, 19 phase II trials, and two phase III clinical trials. Oncolytic viruses are feverously being evaluated in oncology with over 30 different types of oncolytic viruses being explored either as a single agent or in combination with other antitumor agents. To date, only one oncolytic virus therapy has received an FDA approval but advances in bioengineering techniques and our understanding of immunomodulation to heighten oncolytic virus replication and improve tumor kill raises optimism for its future drug development.en_US
dc.description.urihttps://doi.org/10.3390/ijms21207505en_US
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofInternational journal of molecular sciencesen_US
dc.subjectclinical trialsen_US
dc.subjectimmunotherapyen_US
dc.subjectoncolytic virusesen_US
dc.titleClinical Application of Oncolytic Viruses: A Systematic Review.en_US
dc.typeArticleen_US
dc.typeOtheren_US
dc.identifier.doi10.3390/ijms21207505
dc.identifier.pmid33053757
dc.source.volume21
dc.source.issue20
dc.source.countrySwitzerland


This item appears in the following Collection(s)

Show simple item record